Entrapping Digestive Enzymes with Engineered Mesoporous Silica Particles Reduces Metabolic Risk Factors in Humans

Engineered mesoporous silica particles (MSP) are thermally and chemically stable porous materials composed of pure silica and have attracted attention for their potential biomedical applications. Oral intake of engineered MSP is shown to reduce body weight and adipose tissue in mice. Here, clinical data from a first‐in‐humans study in ten healthy individuals with obesity are reported, demonstrating a reduction in glycated hemoglobin (HbA1c) and low‐density lipoprotein cholesterol, which are well‐established metabolic and cardiovascular risk factors. In vitro investigations demonstrate sequestration of pancreatic α‐amylase and lipase in an MSP pore‐size dependent manner. Subsequent ex vivo experiments in conditions mimicking intestinal conditions and in vivo experiments in mice show a decrease in enzyme activity upon exposure to the engineered MSP, presumably by the same mechanism. Therefore, it is suggested that tailored MSP act by lowering the digestive enzyme availability in the small intestine, resulting in decreased digestion of macronutrient and leading to reduced caloric uptake. This novel MSP based mechanism‐of‐action, combined with its excellent safety in man, makes it a promising future agent for prevention and treatment of metabolic diseases. Oral intake of mesoporous silica particles (MSP) results in reduced glycated hemoglobin and low‐density lipoprotein in healthy individuals with obesity. In vitro, ex vivo, and in vivo experiments show sequestration of pancreatic α‐amylase and lipase by MSP that results in a decrease in digestive enzymes activity. MSP show promising potential for prevention and treatment of metabolic diseases.